Inhibitors of the Maillard Reaction and AGE Breakers as Therapeutics for Multiple Diseases

Prakash Reddy; Ayse Beyaz

doi:10.1016/j.drudis.2006.05.016

Inhibitors of the Maillard Reaction and AGE Breakers as Therapeutics for Multiple Diseases

Prakash Reddy
, Ayse Beyaz

Missouri University of Science and Technology

Research output: Contribution to journal › Article › peer-review

Abstract

The Maillard reaction is a complex series of reactions that involve reducing-sugars and proteins, giving a multitude of end-products that are known as advanced glycation end-products (AGEs). AGEs can contribute to the pathogenesis of diabetes and neurological diseases such as Alzheimer's disease. AGEs also play a major role in vascular stiffening, atherosclerosis, osteoarthritis, inflammatory arthritis and cataracts. Thus, AGE inhibitors and AGE breakers offer a potential strategy as therapeutics for diverse diseases. Various AGE inhibitors have been developed in recent years, and their underlying mechanism is based on the attenuation of glycoxidation and/or oxidative stress by the sequestration of metal ions, reactive 1,2-dicarbonyl compounds, and reactive oxygen and reactive nitrogen species.

Original language	American English
Journal	Drug Discovery Today
Volume	11
DOIs	https://doi.org/10.1016/j.drudis.2006.05.016
State	Published - Jul 1 2006

Keywords

2 isopropylidenehydrazono 4 oxo 5 thiazolidinylacetanilide
4 oxo n phenyl 4,5 dihydro 2 [(1 methylethylidene)hydrazino] 5 thiazoleacetamide
Aging
Alzheimer disease
Alzheimer's disease
Animals
Diabetes
Diabetes Mellitus, Type 2
Glycosylation End Products, Advanced
Guanidines
Humans
Hypoglycemic Agents
Maillard Reaction
Maillard reaction
Metformin
Neurodegenerative Diseases
Neuroprotective Agents
Oxidative Stress
Parkinson disease
Reactive Oxygen Species
Receptors, Immunologic
acetamide derivative
acetylsalicylic acid
advanced glycation end product
advanced glycation end product breaker
advanced glycation end product inhibitor
advanced glycation end product receptor
alagebrium
alt 946
aminoguanidine
angiotensin receptor antagonist
antioxidant
arthritis
atherogenesis
atherosclerosis
blocking agent
bromine derivative
can c
carnosine
cataract
cataractogenesis
chemoprophylaxis
clinical trial
clioquinol
deferoxamine
diabetes mellitus
diabetic nephropathy
diabetogenesis
dipeptidyl carboxypeptidase inhibitor
drug mechanism
glycation
homocarnosine
human
hypertension
inflammation
iron chelating agent
metformin
n [[2 (hydrazinoiminomethyl)amino]ethyl]acetamide
n acetylcarnosine
n phenacyl 1,3 thiazolium bromide
neurologic disease
neuroprotection
nifedipine
nonhuman
osteoarthritis
oxidation
oxidative stress
pathogenesis
perindopril
prodrug
pyridorin
pyridoxamine
pyridoxine deficiency
reduction
review
rigidity
soluble advanced glycation end product receptor
tenilsetam
thiazole derivative
unclassified drug
vascular disease

Disciplines

Chemistry

Access to Document

10.1016/j.drudis.2006.05.016License: Unspecified

https://doi.org/10.1016/j.drudis.2006.05.016

Cite this

@article{43cd92ca03b64570a68afae5ebbebb5d,

title = "Inhibitors of the Maillard Reaction and AGE Breakers as Therapeutics for Multiple Diseases",

abstract = " The Maillard reaction is a complex series of reactions that involve reducing-sugars and proteins, giving a multitude of end-products that are known as advanced glycation end-products (AGEs). AGEs can contribute to the pathogenesis of diabetes and neurological diseases such as Alzheimer's disease. AGEs also play a major role in vascular stiffening, atherosclerosis, osteoarthritis, inflammatory arthritis and cataracts. Thus, AGE inhibitors and AGE breakers offer a potential strategy as therapeutics for diverse diseases. Various AGE inhibitors have been developed in recent years, and their underlying mechanism is based on the attenuation of glycoxidation and/or oxidative stress by the sequestration of metal ions, reactive 1,2-dicarbonyl compounds, and reactive oxygen and reactive nitrogen species.",

keywords = "2 isopropylidenehydrazono 4 oxo 5 thiazolidinylacetanilide, 4 oxo n phenyl 4,5 dihydro 2 [(1 methylethylidene)hydrazino] 5 thiazoleacetamide, Aging, Alzheimer disease, Alzheimer's disease, Animals, Diabetes, Diabetes Mellitus, Type 2, Glycosylation End Products, Advanced, Guanidines, Humans, Hypoglycemic Agents, Maillard Reaction, Maillard reaction, Metformin, Neurodegenerative Diseases, Neuroprotective Agents, Oxidative Stress, Parkinson disease, Reactive Oxygen Species, Receptors, Immunologic, acetamide derivative, acetylsalicylic acid, advanced glycation end product, advanced glycation end product breaker, advanced glycation end product inhibitor, advanced glycation end product receptor, alagebrium, alt 946, aminoguanidine, angiotensin receptor antagonist, antioxidant, arthritis, atherogenesis, atherosclerosis, blocking agent, bromine derivative, can c, carnosine, cataract, cataractogenesis, chemoprophylaxis, clinical trial, clioquinol, deferoxamine, diabetes mellitus, diabetic nephropathy, diabetogenesis, dipeptidyl carboxypeptidase inhibitor, drug mechanism, glycation, homocarnosine, human, hypertension, inflammation, iron chelating agent, metformin, n [[2 (hydrazinoiminomethyl)amino]ethyl]acetamide, n acetylcarnosine, n phenacyl 1,3 thiazolium bromide, neurologic disease, neuroprotection, nifedipine, nonhuman, osteoarthritis, oxidation, oxidative stress, pathogenesis, perindopril, prodrug, pyridorin, pyridoxamine, pyridoxine deficiency, reduction, review, rigidity, soluble advanced glycation end product receptor, tenilsetam, thiazole derivative, unclassified drug, vascular disease",

author = "Prakash Reddy and Ayse Beyaz",

year = "2006",

month = jul,

day = "1",

doi = "10.1016/j.drudis.2006.05.016",

language = "American English",

volume = "11",

journal = "Drug Discovery Today",

}

TY - JOUR

T1 - Inhibitors of the Maillard Reaction and AGE Breakers as Therapeutics for Multiple Diseases

AU - Reddy, Prakash

AU - Beyaz, Ayse

PY - 2006/7/1

Y1 - 2006/7/1

N2 - The Maillard reaction is a complex series of reactions that involve reducing-sugars and proteins, giving a multitude of end-products that are known as advanced glycation end-products (AGEs). AGEs can contribute to the pathogenesis of diabetes and neurological diseases such as Alzheimer's disease. AGEs also play a major role in vascular stiffening, atherosclerosis, osteoarthritis, inflammatory arthritis and cataracts. Thus, AGE inhibitors and AGE breakers offer a potential strategy as therapeutics for diverse diseases. Various AGE inhibitors have been developed in recent years, and their underlying mechanism is based on the attenuation of glycoxidation and/or oxidative stress by the sequestration of metal ions, reactive 1,2-dicarbonyl compounds, and reactive oxygen and reactive nitrogen species.

AB - The Maillard reaction is a complex series of reactions that involve reducing-sugars and proteins, giving a multitude of end-products that are known as advanced glycation end-products (AGEs). AGEs can contribute to the pathogenesis of diabetes and neurological diseases such as Alzheimer's disease. AGEs also play a major role in vascular stiffening, atherosclerosis, osteoarthritis, inflammatory arthritis and cataracts. Thus, AGE inhibitors and AGE breakers offer a potential strategy as therapeutics for diverse diseases. Various AGE inhibitors have been developed in recent years, and their underlying mechanism is based on the attenuation of glycoxidation and/or oxidative stress by the sequestration of metal ions, reactive 1,2-dicarbonyl compounds, and reactive oxygen and reactive nitrogen species.

KW - 2 isopropylidenehydrazono 4 oxo 5 thiazolidinylacetanilide

KW - 4 oxo n phenyl 4,5 dihydro 2 [(1 methylethylidene)hydrazino] 5 thiazoleacetamide

KW - Aging

KW - Alzheimer disease

KW - Alzheimer's disease

KW - Animals

KW - Diabetes

KW - Diabetes Mellitus, Type 2

KW - Glycosylation End Products, Advanced

KW - Guanidines

KW - Humans

KW - Hypoglycemic Agents

KW - Maillard Reaction

KW - Maillard reaction

KW - Metformin

KW - Neurodegenerative Diseases

KW - Neuroprotective Agents

KW - Oxidative Stress

KW - Parkinson disease

KW - Reactive Oxygen Species

KW - Receptors, Immunologic

KW - acetamide derivative

KW - acetylsalicylic acid

KW - advanced glycation end product

KW - advanced glycation end product breaker

KW - advanced glycation end product inhibitor

KW - advanced glycation end product receptor

KW - alagebrium

KW - alt 946

KW - aminoguanidine

KW - angiotensin receptor antagonist

KW - antioxidant

KW - arthritis

KW - atherogenesis

KW - atherosclerosis

KW - blocking agent

KW - bromine derivative

KW - can c

KW - carnosine

KW - cataract

KW - cataractogenesis

KW - chemoprophylaxis

KW - clinical trial

KW - clioquinol

KW - deferoxamine

KW - diabetes mellitus

KW - diabetic nephropathy

KW - diabetogenesis

KW - dipeptidyl carboxypeptidase inhibitor

KW - drug mechanism

KW - glycation

KW - homocarnosine

KW - human

KW - hypertension

KW - inflammation

KW - iron chelating agent

KW - metformin

KW - n [[2 (hydrazinoiminomethyl)amino]ethyl]acetamide

KW - n acetylcarnosine

KW - n phenacyl 1,3 thiazolium bromide

KW - neurologic disease

KW - neuroprotection

KW - nifedipine

KW - nonhuman

KW - osteoarthritis

KW - oxidation

KW - oxidative stress

KW - pathogenesis

KW - perindopril

KW - prodrug

KW - pyridorin

KW - pyridoxamine

KW - pyridoxine deficiency

KW - reduction

KW - review

KW - rigidity

KW - soluble advanced glycation end product receptor

KW - tenilsetam

KW - thiazole derivative

KW - unclassified drug

KW - vascular disease

UR - https://scholarsmine.mst.edu/chem_facwork/138

UR - https://doi.org/10.1016/j.drudis.2006.05.016

U2 - 10.1016/j.drudis.2006.05.016

DO - 10.1016/j.drudis.2006.05.016

M3 - Article

VL - 11

JO - Drug Discovery Today

JF - Drug Discovery Today

ER -

Inhibitors of the Maillard Reaction and AGE Breakers as Therapeutics for Multiple Diseases

Abstract

Keywords

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this